Cancer Genetics, Inc. Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update

Download PDF
  • Full-Year 2015 revenues up 77% year-over-year to $18 Million
  • Fourth Quarter revenues up 36% year-over-year to $5.5 Million
  • Closed 2015 with strong cash balance of $19.5 Million
  • Conference call begins at 5:00 p.m. Eastern time today

RUTHERFORD, N.J., March 10, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in enabling precision medicine for oncology diagnostics, announced financial and operating results for the fourth quarter and full-year-ended December 31, 2015 and provided an update on the business progress for 2016.

“Our business continues to scale as we integrate the acquisition of Response Genetics, focus on expanding our biopharma partnerships, and enhance our capabilities to provide both comprehensive immuno-oncology and genomic testing for oncology,” said Panna Sharma, CEO & President of Cancer Genetics, Inc. “In addition, CGI’s presence is growing both clinically and among biopharma companies - our teams are currently working with 8 of the top 10 pharma companies, and we have agreements with 24 payers, managed care providers, and insurance companies that cover nearly 180 million lives.”

Highlights for the quarter and year included:

  • Fourth quarter revenues were $5.5 million, up 36% from $4.0 million in the fourth quarter of 2014, with $3.0 million from BioPharma Services, $2.4 million from Clinical Services, and $0.2 million from Discovery Services
     
  • Full-Year revenue for 2015 was $18.0 million, up 77% from $10.2 million for the 12-months ended December 31, 2014
    • BioPharma Services revenue, was $11.6 million, an increase of 106% from $5.6 million over 2014
    • Clinical Services revenue was $5.7 million compared to $4.4 million during 2014
    • Discovery Services generated $0.8 million in revenue
    • Gross profit margins improved to 22%, or $3.9 million, as compared to 17%, or $1.7 million, in the 12-months ended December 31, 2014
    • Cash & cash equivalents at December 31, 2015, were $19.5 million, as compared to $25.6 million at December 31, 2014

“As we look ahead in 2016, we see multiple growth drivers impacting our business.  The increasing number of oncology clinical trials utilizing both genomic and immune-based markers is expected to continue to drive strong demand for our products and services.  In addition, our ability to offer a comprehensive oncology-focused menu of tests, positions us as an ideal partner for healthcare systems,” continued Mr. Sharma.  “We will also be launching a number of innovative tests in 2016, including a multiple myeloma panel with the Mayo Clinic, a NGS-based lung cancer panel and a NGS-based panel for hereditary cancers. We have established a global infrastructure, collaborative relationships with academic and research centers, and a strong portfolio of proprietary genomic tests and capabilities.”

KEY 2015 ACHIEVEMENTS & RECENT CORPORATE HIGHLIGHTS

  • Awarded largest clinical trial in company history to provide comprehensive testing for global, multi-year Chronic Lymphocytic Leukemia trial
  • Closed $12 million public offering to strengthen balance sheet
  • Acquisition of the operations & assets of Response Genetics, Inc. (RGI) included the FDA-cleared Tissue-Of-Origin test. The RGI acquisition is expected to add $10 million in annual revenue during 2016
  • Launched a Next-Generation Sequencing (NGS)-based panel targeting the five most common solid tumors for the East Indian and Asian markets
  • Launched Focus::Myeloid™, a comprehensive NGS-based genomic panel for the improved diagnosis, prognosis, and clinical management of myeloid cancer patients
  • Entered into a strategic alliance with the Laboratory Services group of ICON plc, the global CRO, further expanding CGI’s global reach
  • Launched comprehensive immuno-oncology testing portfolio for both solid tumors and blood based cancers
  • Received $1.2 million in non-dilutive funding through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
  • Presented results from collaborative studies with partners including CGI’s joint venture with Mayo Clinic, Oncospire Genomics, in addition to Memorial Sloane Kettering, Beth Israel Deaconess, Keck School of Medicine at USC, and Weill Cornell Medical College
     
Conference Call & Webcast    
Thursday, March 10th @ 5:00pm Eastern Time  
Domestic:   888-438-5525
International:   719-325-2448
Conference ID:   9859224
Webcast:   http://public.viavid.com/index.php?id=118421
   
Replays – Available through March 24, 2016  
Domestic:   877-870-5176
International:   858-384-5517
Conference ID:   9859224
     

About Cancer Genetics

Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:              

Internet: http://www.cancergenetics.com

Twitter: @Cancer_Genetics

Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended September 30, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

 
CANCER GENETICS, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
(in thousands, except par value)
     
     
    December 31,
    2015   2014
ASSETS        
CURRENT ASSETS        
Cash and cash equivalents   $ 19,459     $ 25,554  
Accounts receivable, net of allowance for doubtful accounts of 2015 $664; 2014 $251   6,621     5,028  
Other current assets   2,118     1,173  
Total current assets   28,198     31,755  
FIXED ASSETS, net of accumulated depreciation   6,069     4,310  
OTHER ASSETS        
Restricted cash   300     6,300  
Patents and other intangible assets, net of accumulated amortization   1,727     503  
Investment in joint venture   341     1,048  
Goodwill   12,029     3,187  
Other   220     2  
Total other assets   14,617     11,040  
Total Assets   $ 48,884     $ 47,105  
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)        
CURRENT LIABILITIES        
Accounts payable and accrued expenses   $ 7,579     $ 3,763  
Obligations under capital leases, current portion   122     59  
Deferred revenue   831     544  
Bank term note, current portion   1,333      
Total current liabilities   9,865     4,366  
Obligations under capital leases   276     300  
Deferred rent payable and other   315     348  
Line of credit       6,000  
Warrant liability   17     52  
Acquisition note payable       560  
Deferred revenue, long-term   752     925  
Bank term note   4,642      
Total Liabilities   15,867     12,551  
STOCKHOLDERS’ EQUITY        
Preferred stock, authorized 9,764 shares $0.0001 par value, none issued        
Common stock, authorized 100,000 shares, $0.0001 par value, 13,652 and 9,821 shares issued and outstanding as of December 31, 2015 and 2014, respectively   1     1  
Additional paid-in capital   131,167     112,520  
Accumulated deficit   (98,151 )   (77,967 )
Total Stockholders’ Equity   33,017     34,554  
Total Liabilities and Stockholders’ Equity   $ 48,884     $ 47,105  

 

 
CANCER GENETICS, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(in thousands, except per share amounts)
       
       
  Three Months Ended December 31   Twelve Months Ended December 31
  2015   2014   2015   2014
Revenue $ 5,484     $ 4,035     $ 18,040     $ 10,199  
Cost of revenues 4,756     3,094     14,098     8,453  
Gross profit 728     941     3,942     1,746  
Operating expenses:              
Research and development 1,148     1,529     5,483     4,622  
General and administrative 5,031     4,138     14,567     12,369  
Sales and marketing 1,726     1,226     5,269     3,964  
Total operating expenses 7,905     6,893     25,319     20,955  
Loss from operations (7,177 )   (5,952 )   (21,377 )   (19,209 )
Other income (expense):              
Interest expense (117 )   (65 )   (344 )   (473 )
Interest income 19     17     49     74  
Change in fair value of warrant liability 17     93     35     417  
Change in fair value of acquisition note payable 360     198     269     198  
Total other income (expense) 279     243     9     216  
Loss before income taxes (6,898 )   (5,709 )   (21,368 )   (18,993 )
Income tax (benefit) (1,184 )   (536 )   (1,184 )   (2,350 )
Net (loss) $ (5,714 )   $ (5,173 )   $ (20,184 )   $ (16,643 )
Basic net (loss) per share $ (0.47 )   $ (0.54 )   $ (1.96 )   $ (1.76 )
Diluted net (loss) per share $ (0.48 )   $ (0.55 )   $ (1.96 )   $ (1.80 )
Basic weighted average shares outstanding 12,048     9,642     10,298     9,449  
Diluted weighted average shares outstanding 12,048     9,642     10,299     9,462  

 

 
CANCER GENETICS, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(in thousands)
     
     
    Years Ended December 31,
    2015   2014
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss   $ (20,184 )   $ (16,643 )
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation   1,503     810  
Amortization   159     28  
Provision for bad debts   413     215  
Stock-based compensation   2,834     3,835  
Change in fair value of acquisition note payable   269     (198 )
Change in fair value of Gentris contingent consideration   (207 )    
Change in fair value of warrant liability   (35 )   (417 )
Amortization of loan guarantee, financing fees and debt issuance costs   8     311  
Loss in equity-method investment   707     940  
Change in working capital components:        
Accounts receivable   (1,662 )   (1,657 )
Other current assets   (384 )   (199 )
Other non-current assets   (101 )    
Accounts payable, accrued expenses and deferred revenue   3,114     675  
Deferred rent and other   (33 )   (38 )
          Net cash (used in) operating activities   (13,599 )   (12,338 )
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of fixed assets   (1,008 )   (1,374 )
(Increase) decrease in restricted cash   6,000     (6,000 )
Patent costs   (137 )   (130 )
Investment in joint venture       (1,000 )
Cash used in acquisition of Gentris, net of cash received       (3,181 )
Cash from acquisition of BioServe       312  
Cash used in acquisition of Response Genetics   (7,495 )    
          Net cash (used in) investing activities   (2,640 )   (11,373 )
CASH FLOWS FROM FINANCING ACTIVITIES        
Principal payments on capital lease obligations   (83 )   (44 )
Payment of equity issuance costs   (117 )    
Proceeds from public offerings of common stock, net of offering costs   10,353      
Proceeds from warrant exercises   1     178  
Proceeds from option exercises   23     79  
Payment of debt issuance costs   (33 )    
Principal payments on notes payable       (408 )
          Net cash provided by (used in) financing activities   10,144     (195 )
          Net increase (decrease) in cash and cash equivalents   (6,095 )   (23,906 )
CASH AND CASH EQUIVALENTS        
Beginning   25,554     49,460  
Ending   $ 19,459     $ 25,554  
SUPPLEMENTAL CASH FLOW DISCLOSURE        
Cash paid for interest   $ 240     $ 128  
SUPPLEMENTAL DISCLOSURE OF NONCASH        
INVESTING AND FINANCING ACTIVITIES        
Fixed assets acquired through capital lease arrangements   $     $ 42  
Value of shares issued as partial consideration to purchase Gentris and BioServe       1,516  
Value of shares issued as partial consideration to purchase Response Genetics   5,436      
Cashless exercise of derivative warrants       125  
Net tangible assets acquired via acquisition   2,843     1,255  

 

Contact:
Media Contact:    
Cancer Genetics, Inc.   
Marie-Agnes Patrone-Michellod, PhD.
Tel: 201.528.9200    
Email: marie.michellod@cgix.com 

Investor Contact:
LifeSci Advisors, LLC
Hans Vitzthum
212-915-2568
hans@lifesciadvisors.com

Primary Logo

 

Source: Cancer Genetics, Inc.

Discover Cancer Genetics Incorporated »

Our Research
With unparalleled excellence in oncology, our team is dedicated to empowering personalized cancer treatment.
Our Media
Stay current with the latest company news, articles, videos, and webinars.
Our Partners
CGI has established strong research collaborations with key thought leaders in oncology and major cancer centers in the U.S. and abroad.
Reports
Click here to login and view your reports.